Author:
D'Souza Susan S.,Selmin Francesca,Murty Santos B,Qiu Wei,Thanoo BC,DeLuca Patrick P
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Okada H. One-and three-month release injectable microspheres of the LH-RH superagonist leuprorelin acetate. Adv Drug Deliv Rev. 1997; 28: 43–70.
2. Pucarelli I, Segni M, Ortore M, Arcadi E, Pasquino AM. Effects of combined gonadotropin-releasing hormone agonist and growth hormone therapy on adult height in precocious puberty: a further contribution. J Pediatr Endocrinol Metab. 2003; 16: 1005–1010.
3. Fontana D, Mari M, Martinelli A, et al. 3-month formulation of goserelin acetate (‘Zoladex’ 10.8-mg depot) in advanced prostate cancer: results from an Italian, open, multicenter trial. Urol Int. 2003; 70: 316–320.
4. Alloul K, Sauriol L, Lafortune L. Meta-analysis and economic evaluation of LH-RH agonists' depot formulations in advanced prostatic carcinoma. Can J Urol. 1998; 5: 585–594.
5. Garnick MB, Fair W. Combating prostate cancer. Sci Am. 1998; 279: 74–83.
Cited by
25 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献